- Home
- MREO vs DCTH Comparison
MREO vs DCTH Comparison
Compare MREO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | DCTH |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 350.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MREO | DCTH |
|---|---|---|
| Price | $2.02 | $10.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.20 | ★ $22.60 |
| AVG Volume (30 Days) | ★ 2.4M | 682.8K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $500,000.00 | ★ $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | $131.12 | $38.84 |
| P/E Ratio | ★ N/A | $291.54 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $1.47 | $8.12 |
| 52 Week High | $3.88 | $18.23 |
Technical Indicators
Market Signals| Indicator | MREO | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 55.89 |
| Support Level | $1.89 | $9.84 |
| Resistance Level | $2.37 | $10.28 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 40.48 | 57.50 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.